Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Future growth could also be driven by ... a separate study also underway in diabetes. Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound ...

Novo Nordisk's obesity therapy Wegovy put in another strong sales performance ... Mounjaro for diabetes and obesity therapy Zepbound – as well as the likely entrance of new players in the ...

The manufacturer of Ozempic, Novo Nordisk, also produces Wegovy, an injectable containing the same active ingredient, semaglutide, that is FDA-approved to treat overweight and obesity in adults ...

With more than 50 million redeemed miles under her belt, Becky Pokora is a rewards travel expert. She's been writing about credit cards and reward travel since 2011 with articles on Forbes Advisor ...